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ABSTRACT

Objective: Herein, we describe the disease burden and age-related changes of congenital-onset
myotonic dystrophy (CDM) in childhood.

Methods: Children with CDM and age-matched controls aged 0 to 13 years were enrolled. Participants were divided into cohorts based on the following age groups: 0–2, 3–6, and 7–13 years.
Each cohort received age-appropriate evaluations including functional testing, oral facial
strength testing, neuropsychological testing, quality-of-life measurements, and ECG.
Independent-samples t test or Wilcoxon 2-sample test was used to compare the differences
between children with CDM and controls. Probability values less than 0.05 are reported as
significant.
Results: Forty-one participants with CDM and 29 healthy controls were enrolled. The 6-minute
walk was significantly different between CDM (258.3 m [SD 176.0]) and control participants
(568.2 m [SD 73.2]). The mean lip force strength was significantly different in CDM (2.1 N [SD
2.8)] compared to control participants (17.8 N [SD 7.6]). In participants with CDM, the mean IQ
(65.8; SD 18.4) was 3 SDs below the mean compared to standardized norms. Measurements
of grip strength, sleep quality, and quality of life were also significantly different. Strength measures (oral facial strength, grip strength, and 6-minute walk) correlated with each other but not with
participant IQ.
Conclusions: This work identifies important phenotypes associated with CDM during childhood.
Several measures of strength and function were significantly different between participants with
CDM and controls and may be useful during future therapeutic trials. Neurology® 2016;87:160–167
GLOSSARY
CDM 5 congenital myotonic dystrophy; DM1 5 myotonic dystrophy type 1; FVC 5 forced vital capacity; PDSS 5 Pediatric
Daytime Sleepiness Scale; PedsQL 5 Pediatric Quality of Life Inventory; 6MWD 5 6-minute walk test distance.

Supplemental data
at Neurology.org

Myotonic dystrophy type 1 (DM1) is an autosomal dominant, multisystemic disorder that is
caused by a CTGn repeat in the DMPK gene.1–3 Congenital myotonic dystrophy (CDM)
represents the most severe form of myotonic dystrophy and results from a large expansion of
the CTGn repeat between parent and child. Symptoms are present at birth and include severe
hypotonia, respiratory failure, gastroparesis, and talipes equinovarus.4,5 These symptoms are
distinct from those described in adults with DM1, who typically present with distal weakness,
myotonia, and early-onset cataracts. During the first year of life, there is a 30% mortality for
those infants ventilated for greater than 3 months.6 Beyond the first year of life, there is limited
information about the natural history of CDM.
Clinically, children with CDM are observed to have significant improvement in respiratory
and motor areas; however, as patients get older, myotonia, cardiac arrhythmias, and other features typical of adult-onset DM1 emerge. Both intellectual impairment and oral facial weakness
cause significant burden during childhood.7,8 In addition to intellectual impairment, there is
evidence of autism spectrum disorder and attention-deficit/hyperactivity disorder.7,9 A prior
cross-sectional survey study identified difficulty with communication and problems with hands
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and fingers as the issues that reduce quality of
life in children.10 While this work has helped
to characterize the disease burden in children
with CDM, it did not serially evaluate patients
using clinical assessments.
The objectives of this study are 2-fold:
first, to identify the disease burden associated
with CDM in childhood at different ages; and
second, to determine the feasibility and discriminatory ability of a set of relevant and
commonly used outcome measures in this
population.
METHODS Participants. Children with CDM between the
ages of 0 and 13 years were enrolled at the University of Utah
and Western University. All participants had (1) an onset of
symptoms in the neonatal period requiring 72 hours or more of
hospitalization, and (2) a history of hypotonia, respiratory failure,
or feeding difficulty. In addition, participants were required to
have genetic testing confirming a CTG repeat expansion in the
DMPK gene greater than 200 repeats. Individuals were not
included if they had any other non-DM1 illness or significant
trauma within 1 month. Healthy controls were required to be
ages 0 to 13 years with no other significant medical history or
medication use.

Study procedures. All study procedures were conducted over
a 2-day interval. Demographic data, medical history, and
respiratory function were collected on all individuals.
Standard protocol approvals, registrations, and patient
consents. All study procedures were approved by the institutional review board of both institutions.

Functional testing. The 6-minute walk was performed as
previously described in children ages 3 to 13 years.11 Maximum
voluntary isometric contraction of hand grip was performed
(JAMAR Plus; Sammons Preston). Lateral pinch was measured
using the JAMAR Plus digital pinch gauge (Sammons Preston).
Oral facial testing. Both children with CDM and healthy controls received 2 quantitative measures of oral facial strength. A
speech therapist with experience in these measures performed
the training for both sites. The Iowa Oral Performance Instrument consists of a pressure bulb attached to a manometer. The
pressure bulb was placed against the tongue and participants were
asked to push the bulb to the alveolar ridge. Maximum pressure
was averaged over 3 efforts. The Lip Force Meter was modified
from prior study designs. A plastic mouth guard with the bite
guard removed was attached to a force meter and was placed anterior to the teeth, with the lips closed around it. Participants were
asked to hold the guard inside their mouths while the examiner
applied steady force to remove it. The maximum force to remove
the guard from the participants’ mouths was recorded, and averaged over 3 attempts.
Neuropsychological testing. Cognitive function in participants with CDM was assessed by an experienced neuropsychometrist or psychologist. Full-scale IQ was assessed using the
Wechsler Preschool and Primary Scale of Intelligence (3rd
edition) and the Wechsler Intelligence Scale for Children (4th
edition) depending on age. Estimated IQ was assessed using the
Wechsler Preschool and Primary Scale of Intelligence–III Block
Design and Vocabulary or Receptive Vocabulary subtests, or the

Wechsler Intelligence Scale for Children–IV Block Design and
Vocabulary subtests. Control participants did not undergo
neuropsychological assessment because of previously established
norms. The Pediatric Sleep Questionnaire and the Pediatric
Daytime Sleepiness Scale (PDSS) were used to evaluate sleep
quality and daytime sleepiness in participants with CDM.
Quality of life was assessed for participants with CDM using
the Pediatric Quality of Life Inventory (PedsQL) parent proxy
measure.

Cardiac testing. All children with CDM had a standard 12-lead
ECG.

Respiratory testing. Forced vital capacity (FVC) measurements
were attempted on 16 participants with CDM who were older
than 6 years. The MIR Spirobank and the CareFusion MicroLab
spirometers were used to collect FVC. FVC was calculated based
on height, weight, age, and sex. A mouthpiece was used along
with the open circuit method and verbal encouragement was
given during rapid exhalation in an upright and seated position.
Up to 6 trials were attempted per participant.
Gastrointestinal testing. Participants and parents were queried
regarding the presence of abdominal pain association with food,
diarrhea, constipation, and use of motility agents.

Statistical analyses. Descriptive statistics were conducted on
the overall sample and the CDM and control groups.
Independent-samples t test or Wilcoxon 2-sample test was used
to compare the differences between groups on functional testing
(6-minute walk and grip and pinch myometry), oral facial
strength testing (lip force and tongue strength), and
neuropsychological testing (IQ, PDSS, and PedsQL), adjusting
for age and sex. All measures were evaluated by age, a high
(.1,000 CTG repeats) and low (,1,000 CTG repeats) group.
Pearson correlation was performed to understand the
relationships among IQ, 6-minute walk, lip force, and grip
myometry. All analyses were conducted with SAS 9.4 statistical
software (SAS Institute, Cary, NC). Probability values less than
0.05 were considered significant.

Based on eligibility criteria, 43 children
with CDM were identified. The study enrolled 41
children with CDM and 29 healthy controls. Mean
age of the children with CDM was 6.8 years (SD
3.3) and the mean CTG repeat length was 1,200
(SD 500). Detailed demographic data, including
age, sex, CTG repeat length, and respiratory status
are provided in table 1.

RESULTS

Functional testing. Participants younger than 2 years
did not participate in functional testing. For those
older than 2 years, not all children with CDM were
able to complete each task, either because they were
nonambulatory (19.0%) or because behavioral difficulties limited their ability to complete the task
(11.0%). On the 6-minute walk test distance
(6MWD), children with CDM (n 5 33) walked
258.3 m (SD 176), while healthy controls walked
568.3 m (SD 73.2) (p , 0.001). There are agebased normative values for children’s 6MWD.12
Using these, children with CDM who were older
than 5 years averaged the 1st percentile (SD 0.03;
range 0%–12.7%), while children in the control
Neurology 87
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Table 1

Demographic data

Demographic

Participants with congenital
myotonic dystrophy (n 5 41)

Control participants
(n 5 29)

Age, y (SD)

6.8 (3.3)

9.1 (3.1)

Participants in cohort 1, aged 0–2 y, n

7

2

Participants in cohort 2, aged 3–6 y, n

18

5

Participants in cohort 3, aged 7–13 y, n

16

22

Female, %

49

59

Ethnicity, %

12 Hispanic, 88 non-Hispanic

7 Hispanic, 93 non-Hispanic

Race, %

98 Caucasian, 2 Asian

100 Caucasian

Mean CTG repeat length (SD)

1,245.97 (474.91)

NA

Mean duration of respiratory support at
birth, wk (range)

25.9 (1–156)

0

Current respiratory support, %
(mean duration of use during day)

7.0 BiPAP (13.3 h), 7.0
supplemental oxygen (9.6 h)

0

Abbreviations: BiPAP 5 bilevel positive airway pressure; NA 5 not applicable.

group were in the 24th percentile (SD 0.24; range
0%–95.3%). Older children in both cohorts walked
longer 6MWD compared to younger children. There
was not a decline in the distance walked in the CDM
cohort with age (figure 1A). When comparing higher
CTG repeat lengths ($1,000) to lower CTG repeat
lengths (,1,000), there was no difference in 6MWD
between the 2 groups (figure 1B). Children with
CDM (n 5 29) had a mean right grip strength of
5.3 kg (SD 4.5) compared to a right grip strength of
15 kg (SD 5.2) in healthy controls (p , 0.001). On
right pinch strength, children with CDM (n 5 28)
had a mean of 1.7 kg (SD 1.2) compared to 4.4 kg
(SD 1.3) (p , 0.001). There was a gradual
improvement in grip and pinch strength with age
regardless of CDM status (figure 1, C and E).
There was no difference in how the lower and
higher CTG repeat groups performed by age in grip
and pinch strength (figure 1, D and F). We evaluated
whether prolonged respiratory support at birth
affected functional outcomes. There was no
significant difference in the 6MWD or grip strength
when comparing those requiring more or less than 4
weeks of respiratory support at birth (figure e-1 on the
Neurology® Web site at Neurology.org).
Oral facial strength testing. Children with CDM (n 5
23) had a reduction in lip strength (2.1 N [SD 2.8])
compared to healthy controls (17.8 N [SD 7.6]) (p ,
0.001). There was also a reduction in tongue strength
in children with CDM (11.5 kPa [SD 7.8]) compared
to healthy controls (41.8 kPa [SD 12.6]) (p , 0.001)
as measured by the Iowa Oral Performance Instrument. In addition, children with CDM did not have
the same improvement with age as healthy controls
(figure 2, A and B). There was no association with
CTG repeat length and lip or tongue force.
162
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Neuropsychological testing. The mean estimated IQ
among children with CDM was 65.8 (SD 18.4),
which is 3 SDs below the mean compared to standardized norms. There was no clear improvement
or decline in IQ by age or CTG repeat length
(figure 3, A and B). On the PDSS, the measure
of daytime sleepiness, the mean score was 11.9
(SD 6.48). There was an increase in daytime sleepiness with age and CTG repeat length (figure 3, C
and D). The mean Pediatric Sleep Questionnaire
score, a measure of sleep quality, was 24.2 (SD
8.83). There was a clear decline in sleep quality
with age but not with CTG repeat length (figure 3,
E and F). Finally, on the parent proxy PedsQL, the
mean score was 56.3 (SD 15.0). There was
a decline in quality of life with age in both groups,
and no clear difference with CTG repeat length
(figure 3, G and H).
Cardiac testing. There were 5 children with CDM
who had cardiac issues, which were detected with
ECG. These included left anterior fascicular block
(1 child), prolonged QT (2 children), and firstdegree AV block (2 children).
Respiratory testing. All participants were able to wean
from respiratory support required during the neonatal period, and a minority required ongoing nighttime positive pressure ventilation (table 1). FVC
measurements were attempted in children with
CDM between the ages of 6 and 13 (n 5 16).
Thirty-eight percent of the children with CDM
(6/16) were able to complete the spirometry
testing. Four of 6 children were able to complete 3
FVC trials, and only 2 of 6 (33.3%) were able to
complete one trial. The remaining 10 participants
refused, were unable to follow directions, or had
severe behavior problems. The average age of
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Figure 1

Functional outcome measures in CDM

(A) Six-minute walk distance by age comparing children with CDM and healthy controls. (B) Six-minute walk distance by age,
comparing high and low CTG repeat lengths. (C) Right grip strength by age with children with CDM and healthy controls. (D)
Right grip strength comparison between children with high or low CTG repeat expansion. (E) Right pinch strength by age
between children with CDM and healthy controls. (F) Right pinch strength by age for children with high or low CTG repeat
expansion. CDM 5 congenital myotonic dystrophy.

children with CDM able to perform the FVC testing
was 11.1 years. The FVC range for children with
CDM was 1.08 to 1.95 L. The mean FVC for
children with CDM was 1.47 L.

difficulties (table 2). IQ did not correlate with the
functional outcome measures. The measures of
strength, mobility, and oral facial strength did correlate with each other (p , 0.0001).

Gastrointestinal testing. Of the 41 children with
CDM, 30% were on a motility agent. The percentage
of children with CDM who endorsed stomach pain
was 9.7%, and 2 of 4 children who did endorse stomach pain reported that it was associated with meals.
Of the 28 children older than 4 years, 39.3% had
fecal incontinence.
We sought to understand the relationships among
cognitive, oral facial, and strength and mobility

DISCUSSION In this study, we were able to apply
a series of frequently used clinical-oriented
outcome measures to demonstrate the significant
and multisystemic disease burden of CDM
in childhood. We demonstrate the global
impairment seen in children with CDM including
differences in physical function, cognitive
function, and quality of life compared to healthy
Neurology 87
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Figure 2

Oral facial strength in CDM

(A) Lip force strength comparison between children with CDM and healthy controls. (B)
Tongue strength comparison between children with CDM and healthy controls. CDM 5 congenital myotonic dystrophy.

controls. While intellectual impairment and oral
facial weakness have been previously reported,
this study further evaluates the disease burden
associated with CDM.7,8,10 Specifically, we
provide evidence of daytime sleepiness and motor
delay that have not been previously reported. The
outcome measures used in the study were chosen
based on past pilot studies by the authors, recent
patient-reported disease burden, and relevant
literature focusing on CDM and other pediatric
neuromuscular disorders.10 Feasibility and
relevancy of certain measurements were based on
age, and while a small proportion of children could
not complete all measures, the feasibility was
generally very good.
To date, few studies have tried to dissect the
complex nature of CDM. Being rigorous in objectifying disease outcome measures, as we have done
in this study, is so critical for several reasons. First,
CDM is a complex dynamic disorder with indices
of disease severity in childhood likely related to
age in a bimodal pattern, trinucleotide repeat size,
and severity of disease at birth. Second, the multisystemic nature of the disorder forces investigators
to measure outcomes in a multiple system domain
164
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to understand the interrelationship and effect of
each on the others. Finally, as we move closer to
clinical trials, there is a pressing need for having feasible outcome measures that discern this population from normal controls and are responsive to
change.
Consistent with our clinical impression, we did
not observe poorer motor function with age, and
in fact, some areas such as grip strength and
6MWD improved with time. Similarly, measures
of oral facial strength were not worse with age. It
is possible that a decline in motor function occurs
at a later age.
IQ in this study did not vary with age. It is possible that aspects of CDM are neurodevelopmental and
will remain static with development. This result will
require validation with a longitudinal study, which
we are currently conducting with the current crosssectional sample reported here. When separating cohorts of larger CTG repeat expansions from smaller
CTG repeat expansions, there was no evidence of
a predictive value on function, with the exception
of daytime sleepiness. Of note, children with CDM
are distinct from adults with DM1, particularly given
the improvement on a number of outcome measures
during their childhood. This underscores the need to
develop a distinct set of outcome measures for children with CDM.
The detection of cardiac arrhythmias in childhood
underscores the importance of regular monitoring at
any age. This reinforces a prior survey study reporting
a prevalence of 24.1% of cardiac arrhythmias in childhood.10 Routine ECGs in childhood should be part of
routine care.
Respiratory failure is frequently seen in the neonatal period of CDM, as previously reported.6,13 We
note that respiratory function universally improved
in our cohort, with no child requiring ventilation later
in life. Several children required persistent nighttime
respiratory assistance, suggesting that pulmonary
function may not be completely normal. The measurement of FVC in this population was limited in
this study, and additional work will be required to
understand the relationship between CDM and respiratory function.
The frequent use of motility agents in children
with CDM suggests that aggressive management of
gastrointestinal symptoms is necessary in children.
There was a significant range of bowel regimens
used, and future studies may consider evaluating
the relative effectiveness of such a diverse set of
medications.
This study also provides a feasibility assessment
of potential outcome measures in therapeutic studies. We note the relative consistency across all
measures as evidence of feasibility, with the
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Figure 3

Intelligence, quality of life, and sleep in CDM

(A) IQ by age in children with CDM. (B) IQ by age, separating high and low CTG repeat expansions. (C) Daytime sleepiness by
age in children with CDM. (D) Daytime sleepiness by age, separating high and low CTG repeat expansions. (E) Pediatric sleep
quality in children with CDM. (F) Pediatric sleep quality by age, separating high and low CTG repeat expansions. (G) Pediatric
quality of life in children with CDM and in healthy controls. (H) Pediatric quality of life in children with high or low CTG repeat
expansions. CDM 5 congenital myotonic dystrophy; PDSS 5 Pediatric Daytime Sleepiness Scale; PedsQL 5 Pediatric
Quality of Life Inventory; PSQ 5 Pediatric Sleep Questionnaire.

exception of IQ. Appropriate age selection of children with CDM may prove difficult, as there is not
a perceptible decline with age, at least in a crosssectional analysis. However, the discriminant
nature of many of the measures compared to controls is important in understanding the potential

for responsiveness to change. An ongoing longitudinal study will assist in refining the course of
CDM throughout childhood.
Finally, this study emphasizes the significant and
multifaceted disease burden in CDM. Specifically,
participants demonstrated differences in measures of
Neurology 87
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Table 2

Correlations between major outcome measurements in patients with congenital myotonic dystrophy

Measure

IQ

6-Minute walk distance, m

IQ

1.00

6-Minute walk distance, m

0.26, p 5 0.218

1.00

Lip force, N

0.24, p 5 0.340

0.59, p , 0.001

1.00

Right grip strength, kPa

0.23, p 5 0.308

0.71, p , 0.001

0.72, p , 0.001

cognitive, physical, gastrointestinal, and cardiac function. Clinical care should reflect this need for comprehensive care and requires a multidisciplinary care
approach.
There are limitations to this study. Few participants lived in the geographic region of the centers.
Many of the participants traveled to the center,
and therefore may have had more resources to participate in our study than patients without the ability to travel. Because of enrollment, the youngest
healthy control that was able to participate in functional measurements (excluding those controls in
the youngest cohort) was age 5, which limited the
ability to fully compare the youngest participants
with CDM. The measurements of CTG repeat
length were obtained from clinical genetic testing,
which was not conducted during the study visit.
Therefore, it is possible there are minor changes in
the CTG repeat length measurement. Cardiac assessments were limited to an ECG and did not
include echocardiography or Holter monitoring.
Therefore, the description is limited to ECG data.
This is a cross-sectional study, so description of disease progression is limited to a between-participant
comparison.
Overall, children with CDM have differences in
speech, cognition, and motor function as compared
to healthy children. Nearly all of these differences
do improve with age. This may suggest that the initial
perinatal difficulties are primarily a neurodevelopmental problem, or that ongoing disease processes in children may be mitigated with growth and development.
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